Cognetivity Neurosciences logo

Cognetivity Neurosciences(OTC) CGNSF

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Cognetivity Neurosciences last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-09
Cognetivity Neurosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-09-28
1 month+0%USD 0.002026-06-25
3 month+0%USD 0.002026-06-25
Year to date+0%USD 0.002025-12-30
1 year+0%USD 0.002025-09-04
3 year-100%USD 0.102023-10-10
5 year-100%USD 0.542021-10-08
Since inception-100%USD 0.352018-10-04

Cognetivity Neurosciences Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$98.97K

Net Income (TTM)

-CA$8.64M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-4.40 (Low)

Price

$0.00

Volume

154,813

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Jan 1, 2027

CGNSF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cognetivity Neurosciences

Cognetivity Neurosciences Ltd. is a healthcare firm focused on advanced cognitive assessment. The company has developed a sophisticated platform for cognitive testing, designed for use across diverse settings including medical facilities, commercial environments, and by individual consumers.

Products and Services
  • Advanced cognitive assessment platform for early detection of cognitive impairment
  • OptiMind, a dedicated wellness application for cognitive health
  • Solutions tailored for medical and commercial environments
Growth Outlook
  • Significant market potential in cognitive health assessment, driven by aging populations
  • Expansion of product offerings to enhance user engagement and market reach
  • Increased partnerships with healthcare providers to broaden service accessibility
Financial Highlights
  • Q3 2023 revenue of 29,156 CAD, a notable increase from previous quarters
  • Trailing twelve months (TTM) gross profit margin at 45.7%, indicating potential for profitability
  • Cash and cash equivalents at 16,570 CAD, supporting ongoing operations and development
Cognetivity Neurosciences Ltd. is positioned in a growing sector with a focus on cognitive health, which is increasingly relevant as populations age. The innovative platform aims to identify early signs of cognitive impairment, potentially transforming how conditions like dementia are diagnosed and managed. The recent revenue growth reflects a positive trend, suggesting that the company is gaining traction in the market. With a solid gross profit margin, there is potential for future profitability as the company scales its operations. The current cash reserves provide a buffer for continued development and operational needs, allowing Cognetivity to pursue strategic initiatives and partnerships that could further enhance its market position.
AI Generated • Sep 20, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Sina Habibi, PhD

Website

www.cognetivity.com

Headquarters

Vancouver, BC V6E 2E9, CA

CGNSF Financials

Key Financial Metrics (TTM)

Gross Margin

45.70%

Operating Margin

-14085.44%

Net Income Margin

-16386.72%

Return on Equity

95.52%

Return on Capital

N/A

Return on Assets

-262.74%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

154.81K

Avg. Volume

3.07K

Financials (TTM)

Gross Profit

-CA$400.64K

Operating Income

-CA$4.42M

EBITDA

-CA$4.07M

Operating Cash Flow

-CA$3.85M

Capital Expenditure

-CA$28.56K

Free Cash Flow

-CA$3.88M

Cash & ST Invst.

CA$16.57K

Total Debt

CA$2.74M

Cognetivity Neurosciences Performance Analysis

Cognetivity Neurosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-01-31CAD 0N/A
20232023-01-31CAD 34,674N/A
Cognetivity Neurosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-01-31N/A
Q12023-04-30-90.8%
Q22023-07-31387.0%
Q32023-10-3143.7%
Cognetivity Neurosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-01-31CAD -0.14N/A
20232023-01-31CAD -0.06-59.8%
Cognetivity Neurosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-01-31-33.6%
Q12023-04-3018.5%
Q22023-07-319.8%
Q32023-10-31-3.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

CA$29.16K

N/A

Gross Profit

-CA$451.14K

-6821.4%

Gross Margin

-15.47%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

2,500

N/A

Net Income

-CA$2.04M

-13.4%

EBITDA

-CA$700.29K

+59.2%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

CA$16.57K

-99.6%

Total Debt

CA$2.74M

+96.2%

Accounts Receivable

CA$251.78K

-52.9%

Inventory

CA$0.00

+100.0%

Long Term Debt

CA$1.37M

+10.2%

Short Term Debt

CA$1.37M

+794.9%

Return on Assets

-2.63%

N/A

Return on Invested Capital

82.30%

N/A

Free Cash Flow

-CA$1.69K

+99.3%

Operating Cash Flow

CA$16.94K

+107.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EMEDElectromedical Technologies, Inc.
$0.00+0.00%
EMYSFEasy Technologies Inc.
$0.02+0.00%
HPMMHemp Naturals, Inc.
$0.00+0.00%
SHWZMedicine Man Technologies, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About CGNSF

What is the current price of Cognetivity Neurosciences?

Cognetivity Neurosciences is trading at $0.00 per share.

What is the 52-week range for Cognetivity Neurosciences?

Over the past 52 weeks, Cognetivity Neurosciences has traded between $0.00 and $0.00.

How much debt does Cognetivity Neurosciences have?

As of the most recent reporting period, Cognetivity Neurosciences reported total debt of CA$4.85M.

How much cash does Cognetivity Neurosciences have on hand?

Cognetivity Neurosciences reported CA$1.68M in cash and cash equivalents in its most recent financial results.

What is Cognetivity Neurosciences’s dividend yield?

Cognetivity Neurosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services